| Ranbaxy\'s Goa manufacturing plant receives MHRA, UK approval | |
|
Pharma major Ranbaxy Laboratories Limited (RLL) announced that the company's dosage forms manufacturing facility in Goa, India, has received approval from Medicines and Healthcare products Regulatory Agency (MHRA), UK, for its tablets manufacturing unit. With this the company can now seek approvals through National filings and Mutual Recognition Procedures (MRP) in 27 EU/EEA member states and various other countries like Australia, New Zealand, Romania etc. The Goa facility also houses a cream and ointment manufacturing block which is approved by ANVISA, Brazil. Ranbaxy's manufacturing capabilities at Goa were augmented recently to cater to the growing global demand for Ranbaxy products. The facility has a team of over 100 employees who are engaged in manufacturing world-class products. The tablet manufacturing unit has a capacity to produce 720 million tablets per annum. Ranbaxy has 19 state-of-the-art manufacturing facilities spread across seven countries. These include 10 plants in India (three active pharmaceutical ingredients facilities and seven dosage forms facilities), four dosage forms (DF) plants in the US and one DF plant each in Ireland, China, Malaysia, Vietnam and Nigeria. These facilities are approved by various international regulatory agencies such as the US FDA, the MHRA-UK, Bfarm Germany, the MCC -South Africa, ANVISA Brazil and TGA-Australia, for a range of products. All these facilities conform and comply to GMP standards. Commenting on the development, Dr Brian Tempest, CEO and Managing Director, RLL, said, ``It is our endeavour to constantly expand and augment our manufacturing capabilities across the globe to keep pace with the growing international business of the company. The Year 2004 witnessed concerted efforts in this direction. This latest approval will allow us to use this facility for manufacturing products for the EU and many other countries.'' Ranbaxy Laboratories Limited, India's largest pharmaceutical company, manufactures and markets brand and generic pharmaceuticals and Active Pharmaceutical Ingredients. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. Ranbaxy's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies" resulting in a number of products under development. The company is selling its products in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 44 countries and manufacturing operations in seven countries. |
India's No.1 Weekly For The Pharmaceutical Industry
Gulf-Goans e-Newsletter is moderated by AlmeidaG(ji) since 1994, and presented by Ulysses Menezes, owner of http://www.goa-world.com website. Any and all postings from Goans are welcomed - be it a Goan business enterprise, a Goan event/programme of cultural heritage, or of a personal nature. This first of its kind Gulf-Goans e-newsletter is dedicated to Goans around the Globe. http://www.goa-world.com/ Team and founders are always the first to get you in the limelight - in the field of sports, politics, social, cultural, educational, other actitivity(ies) or to the benefit of Goans and Goa via its news services from professional journalists and supporters based in Gulf countries and as far as the Americas. Thanks for the support to Goa and Goans.
View this short film:
http://www.JourneyOfAttraction.com
__________________________________________________
Do
You Yahoo!?
Tired of spam? Yahoo! Mail has the best spam protection around
http://mail.yahoo.com
http://www.goa-world.com
http://www.live365.com/stations/61664 Live Konkani Music
http://www.mahableshwar.com/
Addresses:
Post message: [email protected]
Subscribe: [EMAIL PROTECTED]
Unsubscribe: [EMAIL PROTECTED]
List owner: [EMAIL PROTECTED]
URL to this page:
http://www.yahoogroups.com/group/gulf-goans
Yahoo! Groups Links
http://groups.yahoo.com/group/gulf-goans/
[EMAIL PROTECTED]
